Autolus Therapeutics (NASDAQ:AUTL) Upgraded to “Buy” at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a research note released on Monday, MarketBeat Ratings reports. The brokerage currently has $7.60 price target on the stock, up from their prior price target of $7.00.

Several other research firms have also recently issued reports on AUTL. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.15.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $2.99 on Monday. The firm has a market capitalization of $795.62 million, a P/E ratio of -2.47 and a beta of 2.04. The stock has a 50-day simple moving average of $3.88 and a two-hundred day simple moving average of $3.98. Autolus Therapeutics has a fifty-two week low of $2.92 and a fifty-two week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the business earned ($0.26) earnings per share. As a group, analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in Autolus Therapeutics by 253.5% during the second quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after purchasing an additional 821,156 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Autolus Therapeutics in the 3rd quarter worth about $1,082,000. Millennium Management LLC increased its stake in Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after buying an additional 432,503 shares in the last quarter. Finally, Affinity Asset Advisors LLC increased its stake in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after buying an additional 925,000 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.